Date: 2017-03-28
Type of information: Clinical research agreement
Compound:
Company: BMS (USA - NY) The Parker Institute for Cancer Immunotherapy (USA - CA) the Cancer Research Institute (CRI) (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism:
Disease:
Details: • On March 28, 2017, the Parker Institute for Cancer Immunotherapy, BMS and the Cancer Research Institute announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical immuno-oncology studies across the Parker Institute and CRI networks. BMS will work closely with leading Parker Institute and CRI scientists and researchers, soliciting clinical research proposals from their networks and coordinating multi-site collaboration clinical studies to pursue some of the most difficult questions in cancer research. It will provide scientists with an ecosystem of advanced translational tools, precision immunotherapy and cutting-edge bioanalytical expertise to maximize learning and ensure the generation of high quality data to inform future development. The collaboration will build on the Parker Institute model that brings together the nation’s top research institutions to share resources, data and technology to accelerate research through unifying and managing clinical trial design and conducting clinical studies across multi-centers. The Parker Institute currently funds projects across its network of more than 60 laboratories and 300 researchers who work together to advance research and potentially develop new therapies. The Cancer Research Institute will support the collaboration with investment from its Clinical Accelerator venture philanthropy program and access to its global network of leading investigators from around the world. This is the Parker Institute’s first major agreement with a biopharma partner. The institute will continue to build key industry relationships critical for the success of its unique model.
Financial terms:
Latest news:
